Stock Scorecard



Stock Summary for eFFECTOR Therapeutics Inc (EFTR) - $0.03 as of 11/20/2024 11:46:19 PM EST

Total Score

7 out of 30

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for EFTR

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for EFTR

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for EFTR

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for EFTR

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for EFTR (13 out of 90)

Stock Price Rating (Max of 10) 1
Historical Stock Price Rating (Max of 10) 1
Stock Price Trend (Max of 10) 0
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 10
Analyst Buy Ratings (Max of 5) 0
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 0
Price to Earnings (Max of 10) 0

Latest News for for EFTR

Delisting of Securities of CONX Corp.; Priveterra Acquisition Corp. II; Yield10 Bioscience, Inc.; Aesthetic Medical International Holdings Group Ltd.; Breeze Holdings Acquisition Corp.; Quadro Acquisition One Corp.; DermTech, Inc.; TRACON Pharmaceuticals, Inc.; eFFECTOR Therapeutics, Inc.; Dynatronics Corporation; and Canna-Global Acquisition Corp. from The Nasdaq Stock Market 7/16/2024 8:05:00 PM
Dow Jumps 300 Points; Alimera Sciences Shares Spike Higher - Alimera Sciences ( NASDAQ:ALIM ) 6/24/2024 5:06:00 PM
Why eFFECTOR Therapeutics ( EFTR ) Shares Are Down Over 70% - eFFECTOR Therapeutics ( NASDAQ:EFTR ) 6/24/2024 3:26:00 PM
eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq - eFFECTOR Therapeutics ( NASDAQ:EFTR ) 6/24/2024 11:00:00 AM
eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq 6/24/2024 11:00:00 AM
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer 5/20/2024 12:30:00 PM
eFFECTOR Therapeutics ( EFTR ) Plunges 82% as NSCLC Study Fails 4/5/2024 4:58:00 PM
Dow Dips Over 200 Points; RPM International Shares Fall After Q3 Results - Allurion Technologies ( NYSE:ALUR ) , Achilles Therapeutics ( NASDAQ:ACHL ) 4/4/2024 6:39:00 PM
Nasdaq Surges 1%; ConAgra Brands Posts Upbeat Earnings - Allurion Technologies ( NYSE:ALUR ) , Achilles Therapeutics ( NASDAQ:ACHL ) 4/4/2024 3:58:00 PM
Why Is eFFECTOR Therapeutics Stock Plummeting On Thursday? - eFFECTOR Therapeutics ( NASDAQ:EFTR ) 4/4/2024 2:38:00 PM

Financial Details for EFTR

Company Overview

Ticker EFTR
Company Name eFFECTOR Therapeutics Inc
Country USA
Description N/A
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 3/31/2024
Next Earnings Date N/A

Stock Price History

Last Day Price 0.03
Price 4 Years Ago 0.00
Last Day Price Updated 11/20/2024 11:46:19 PM EST
Last Day Volume 8,317
Average Daily Volume 27,436
52-Week High 17.90
52-Week Low 0.00
Last Price to 52 Week Low 0.00%

Valuation Measures

Trailing PE N/A
Industry PE 22.60
Sector PE 40.32
5-Year Average PE 31.90
Free Cash Flow Ratio 0.01
Industry Free Cash Flow Ratio 12.03
Sector Free Cash Flow Ratio 27.97
Current Ratio Most Recent Quarter 1.03
Total Cash Per Share 5.40
Book Value Per Share Most Recent Quarter 0.21
Price to Book Ratio 0.00
Industry Price to Book Ratio 5.31
Sector Price to Book Ratio 20.88
Price to Sales Ratio Twelve Trailing Months 69.65
Industry Price to Sales Ratio Twelve Trailing Months 11.82
Sector Price to Sales Ratio Twelve Trailing Months 7.11
Analyst Buy Ratings N/A
Analyst Strong Buy Ratings N/A

Share Statistics

Total Shares Outstanding 4,704,400
Market Capitalization 141,132
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -57.95%
Reported EPS 12 Trailing Months -12.57
Reported EPS Past Year -2.16
Reported EPS Prior Year -3.96
Net Income Twelve Trailing Months -34,620,000
Net Income Past Year -35,800,000
Net Income Prior Year -22,665,000
Quarterly Revenue Growth YOY 117.00%
5-Year Revenue Growth 0.07%
Operating Margin Twelve Trailing Months 0.00

Balance Sheet

Total Cash Most Recent Quarter 25,400,000
Total Cash Past Year 4,000,000
Total Cash Prior Year 26,300,000
Net Cash Position Most Recent Quarter 5,956,000
Net Cash Position Past Year -16,000,000
Long Term Debt Past Year 20,000,000
Long Term Debt Prior Year 20,000,000
Total Debt Most Recent Quarter 19,444,000
Equity to Debt Ratio Past Year -0.41
Equity to Debt Ratio Most Recent Quarter 0.04
Total Stockholder Equity Past Year -5,795,000
Total Stockholder Equity Prior Year 3,896,000
Total Stockholder Equity Most Recent Quarter 827,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -29,275,000
Free Cash Flow Per Share Twelve Trailing Months -6.22
Free Cash Flow Past Year -29,647,000
Free Cash Flow Prior Year -26,091,000

Options

Put/Call Ratio 0.00
Has Options False
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.01
MACD Signal -0.01
20-Day Bollinger Lower Band -0.01
20-Day Bollinger Middle Band 0.03
20-Day Bollinger Upper Band 0.08
Beta 0.80
RSI 35.03
50-Day SMA 25.50
150-Day SMA 0.00
200-Day SMA 0.00

System

Modified 11/20/2024 11:46:20 PM EST